Lipid profile before and after renal transplantation--a longitudinal study.
BACKGROUND
The data on lipid profile in renal transplant recipients from the Indian subcontinent is scant.


METHODS
Lipid profile was studied in 30 consecutive patients of end stage renal disease before renal transplantation (0 month) and prospectively posttransplantation at 1, 3, and 6 months. The results were compared with 30, age and sex matched, healthy controls. All the patients received triple immunosuppression (prednisolone, azathioprine and cyclosporine).


RESULTS
Pretransplantation, the hypertriglyceridemia and hypercholesterolemia was present in 20% and 7% of the patients and the difference (elevation) in the mean values of various lipid fractions was not significant compared to healthy controls except a fall in HDL (p < .01). After renal transplantation, there was a significant elevation in the mean values of total cholesterol, triglycerides, VLDL, and LDL cholesterol at 1, 3, and 6 months. HDL cholesterol levels remained significantly lower as compared to healthy controls. Although, the mean values of serum triglycerides and cholesterol were significantly higher in diabetic end stage renal disease compared to nondiabetic ESRD, however there was insignificant difference in the lipid profile amongst diabetic and nondiabetic renal allograft recipients.


CONCLUSIONS
Our data shows distinct elevation in the lipids and lipoproteins after renal transplantation and immunosuppressive drugs seem to be the culprit.
Pannu
H S
HS
Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
Singh
D
D
Sandhu
J S
JS
D000328:Adult; D001379:Azathioprine / Q000008:administration & dosage / Q000378:metabolism; D015415:Biomarkers / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000150:complications / Q000378:metabolism / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000150:complications / Q000378:metabolism / Q000628:therapy; D006084:Graft Rejection / Q000453:epidemiology / Q000209:etiology / Q000378:metabolism; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000453:epidemiology; D006977:Hypertension, Renal / Q000150:complications / Q000378:metabolism / Q000628:therapy; D015228:Hypertriglyceridemia / Q000097:blood / Q000453:epidemiology; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000378:metabolism; D015994:Incidence; D007194:India / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000378:metabolism / Q000628:therapy; D016030:Kidney Transplantation; D008137:Longitudinal Studies; D008297:Male; D009400:Nephrosclerosis / Q000150:complications / Q000378:metabolism / Q000628:therapy; D007690:Polycystic Kidney Diseases / Q000150:complications / Q000378:metabolism / Q000628:therapy; D011239:Prednisolone / Q000008:administration & dosage / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D007166:Immunosuppressive Agents; D014280:Triglycerides; D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine